Structure-Based Study to Overcome Cross-Reactivity of Novel Androgen Receptor Inhibitors

Structure-Based Study to Overcome Cross-Reactivity of Novel Androgen Receptor Inhibitors

The mutation-driven transformation of clinical anti-androgen drugs into agonists of the human androgen receptor (AR) represents a major challenge for the treatment of prostate cancer patients. To address this challenge, we have developed a novel class of inhibitors targeting the DNA-binding domain (...

Full description

Bibliographic Details
Main Authors: Mariia Radaeva, Huifang Li, Eric LeBlanc, Kush Dalal, Fuqiang Ban, Fabrice Ciesielski, Bonny Chow, Helene Morin, Shannon Awrey, Kriti Singh, Paul S. Rennie, Nada Lallous, Artem Cherkasov
Format: Article
Language:English
Published: MDPI AG 2022-09-01
Series:Cells
Subjects:
androgen receptor
ligand binding domain
agonism
drug design
X-ray crystallography
inhibitors
Online Access:https://www.mdpi.com/2073-4409/11/18/2785

Internet

https://www.mdpi.com/2073-4409/11/18/2785

Similar Items